Future multicenter studies with larger, prospectively followed cohorts and robust multivariable modeling are needed to validate the diagnostic and prognostic value of galectin-3 and pentraxin-3 in CCS and AF. The gene discussed is PTX3; the disease is atrial fibrillation.